KCM
CNTX icon

Knoll Capital Management’s Context Therapeutics CNTX Stock Holding History

Knoll Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-139,520
Closed -$155K – 26
2022
Q3 		$155K Hold
139,520
– – 0.09% 30
2022
Q2 		$296K Hold
139,520
– – 0.17% 34
2022
Q1 		$303K Buy
+139,520
New +$293K 0.19% 36

Other funds holding CNTX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Knoll Capital Management's CNTX Position: Q4 2022 in Review

Knoll Capital Management sold out of Context Therapeutics (CNTX) in Q4 2022, closing a stake of 139,520 shares — an estimated $155K sold.

Knoll Capital Management first reported a position in CNTX in Q1 2022 and held it in 3 quarters. The position peaked at $303K in Q1 2022. 24 funds tracked by Wall St. Rank hold CNTX as of Q4 2022.

  • Knoll Capital Management reported no remaining Context Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Knoll Capital Management sold 139,520 Context Therapeutics shares in Q4 2022, an estimated $155K.
  • Knoll Capital Management first reported a position in Context Therapeutics in Q1 2022 and held it in 3 quarters.
  • Knoll Capital Management's Context Therapeutics position peaked at $303K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2022.

Based on Knoll Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.